PhiTech Bioinformatics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PhiTech Bioinformatics - overview
Established
2013
Location
-, -, Turkey
Primary Industry
Biotechnology
About
Based in Gebze, Turkey, and founded in 2013, PhiTech Bioinformatics, a. k. a. PhiTech operates as a biotechnology company that focuses on translating genome-wide molecular data into biotechnology solutions primarily for use in precision medicine.
In March 2024, PhiTech Bioinformatics raised USD 1. 1 million in seed funding led by Arya Women Investment Platform, with participation from Arz Portfolio, Simya VC, Vestel Ventures, and ISTCAPITAL. The company provides genomic data analysis services for the diagnosis of genetic diseases, the discovery of candidate genes for undiagnosed rare diseases, and yield improvement in agriculture. PhiTech leverages its RNA-Seq workflows to identify differentially expressed genes, differentially spliced regions, genomic variants, and perturbed molecular pathways, among others.
The company plans to use its proceeds from March 2024 funding for go-to-market activities through their foreign offices and to accelerate R&D processes.
Current Investors
Vestel Ventures, Arya Women Investment Platform, ISTCAPITAL
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Bioinformatics
Website
www.phitech.bio
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
PhiTech Bioinformatics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.